Syntax Research’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
Other funds holding MRNA
TP
Syntax Research's MRNA Position: Q3 2026 in Review
Syntax Research opened a new position in Moderna (MRNA) in Q3 2026: 13 shares worth $2.5K. The stake represents ﹤0.01% of the portfolio and ranks #178 among its holdings. This is a return to the name: Syntax Research previously reported a position in MRNA as recently as Q2 2025.
Syntax Research first reported a position in MRNA in Q4 2023 and has held it in 6 quarters since. The position peaked at $6.68K in Q3 2024. 1,033 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.
- Syntax Research held 13 shares of Moderna worth $2.5K as of Q3 2026.
- Moderna was a new Syntax Research position in Q3 2026.
- Moderna made up ﹤0.01% of Syntax Research's portfolio in Q3 2026, its #178 holding.
- Syntax Research first reported a position in Moderna in Q4 2023 and has held it in 6 quarters since.
- Syntax Research's Moderna position peaked at $6.68K in Q3 2024.
- 1,033 funds tracked by Wall St. Rank held Moderna as of Q3 2026.
Based on Syntax Research's 13F filing for Q3 2026, filed 4 Nov 2026.